(AKZA) Akzo Nobel - Overview
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0013267909
Stock:
Total Rating 42
Risk 76
Buy Signal -0.59
| Risk 5d forecast | |
|---|---|
| Volatility | 23.4% |
| Relative Tail Risk | -5.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -1.90 |
| Character TTM | |
|---|---|
| Beta | 0.438 |
| Beta Downside | 0.277 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.78% |
| CAGR/Max DD | -0.05 |
EPS (Earnings per Share)
Revenue
Description: AKZA Akzo Nobel
Akzo Nobel N.V. produces and sells paints and coatings worldwide. It operates in two segments, Decorative Paints and Performance Coatings. The company offers decorative paints, including paints, lacquers, and varnishes; and a range of mixing machines and color concepts for the building and renovation industry, as well as automotive and specialty coatings. It also provides performance coatings that protect and enhance ships, cars, aircraft, yachts, architectural components, consumer goods, and oil and gas facilities, as well as powder coatings. The company offers its products under the AkzoNobel, Alabastine, Alba, Andercol, Apla, Armstead Trade, Astral, Astral Batiment, AwlGrip, Brikol, Bruguer, Cetabever, Cetol, Chemcraft, Colourland Paints, CONSOLAN, Coral, Cromadex, Cuprinol, Dulux, Dynacoat, Flexa, Glitsa, Grip-Gard, Hammerite, Herbol, Inca, Innenweis, Interlux, International, Interpon, Lesonal, Levis, Luxol, Mactra, Marshall, Mason CT, Mauvilac, Maxilite, Modern Classikk, Molto, Nordsjo, Oxirite, Pintuco, Pinotex, Polycell, Polyfilla, Procolor, Protecto, Relest, Resicoat, Sadolin, Salcomix, Savana, Sea Hawk, Sikkens, Sparlack, Taubmans, Titanlux, Trimetal, U-Tech, Vivechrom, VPowdertech, Wanda, Xyladecor, Xylazel, and Zweihorn brands. The company serves energy, packaging, infrastructure, and shipbuilding and maintenance industries, as well as general industries, such as agricultural and construction equipment, construction-related steel, metal fabrication, pipes, appliances, and transportation. The company was formerly known as Akzo NV and changed its name to Akzo Nobel N.V. in 1994. Akzo Nobel N.V. was founded in 1646 and is headquartered in Amsterdam, the Netherlands.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 635.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 18.25% < 20% (prev 10.33%; Δ 7.93% < -1%) |
| CFO/TA 0.07 > 3% & CFO 915.0m > Net Income 635.0m |
| Net Debt (3.24b) to EBITDA (1.54b): 2.10 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (171.8m) vs 12m ago 0.61% < -2% |
| Gross Margin: 39.86% > 18% (prev 0.40%; Δ 3946 % > 0.5%) |
| Asset Turnover: 72.04% > 50% (prev 75.17%; Δ -3.13% > 0%) |
| Interest Coverage Ratio: 6.26 > 6 (EBITDA TTM 1.54b / Interest Expense TTM 186.0m) |
Altman Z''
| A: 0.13 (Total Current Assets 6.06b - Total Current Liabilities 4.21b) / Total Assets 13.95b |
| B: error (Retained Earnings missing) |
| C: 0.08 (EBIT TTM 1.16b / Avg Total Assets 14.10b) |
| D: 0.51 (Book Value of Equity 4.66b / Total Liabilities 9.13b) |
Beneish M -2.92
| DSRI: 1.21 (Receivables 2.61b/2.27b, Revenue 10.16b/10.71b) |
| GMI: 1.02 (GM 39.86% / 40.49%) |
| AQI: 0.95 (AQ_t 0.40 / AQ_t-1 0.42) |
| SGI: 0.95 (Revenue 10.16b / 10.71b) |
| TATA: -0.02 (NI 635.0m - CFO 915.0m) / TA 13.95b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of AKZA shares?
As of February 28, 2026, the stock is trading at EUR 59.62 with a total of 741,112 shares traded.
Over the past week, the price has changed by -1.16%, over one month by +2.16%, over three months by +6.39% and over the past year by +3.20%.
Over the past week, the price has changed by -1.16%, over one month by +2.16%, over three months by +6.39% and over the past year by +3.20%.
Is AKZA a buy, sell or hold?
Akzo Nobel has no consensus analysts rating.
What are the forecasts/targets for the AKZA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.3 | 14.5% |
| Analysts Target Price | - | - |
AKZA Fundamental Data Overview February 28, 2026
Market Cap USD = 12.07b (10.20b EUR * 1.1832 EUR.USD)
P/E Trailing = 16.1189
P/E Forward = 13.4409
P/S = 1.0043
P/B = 2.4845
P/EG = 1.0419
Revenue TTM = 10.16b EUR
EBIT TTM = 1.16b EUR
EBITDA TTM = 1.54b EUR
Long Term Debt = 3.67b EUR (estimated: total debt 4.86b - short term 1.19b)
Short Term Debt = 1.19b EUR (from shortTermDebt, last quarter)
Debt = 4.86b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.24b EUR (from netDebt column, last quarter)
Enterprise Value = 13.14b EUR (10.20b + Debt 4.86b - CCE 1.92b)
Interest Coverage Ratio = 6.26 (Ebit TTM 1.16b / Interest Expense TTM 186.0m)
EV/FCF = 21.69x (Enterprise Value 13.14b / FCF TTM 606.0m)
FCF Yield = 4.61% (FCF TTM 606.0m / Enterprise Value 13.14b)
FCF Margin = 5.97% (FCF TTM 606.0m / Revenue TTM 10.16b)
Net Margin = 6.25% (Net Income TTM 635.0m / Revenue TTM 10.16b)
Gross Margin = 39.86% ((Revenue TTM 10.16b - Cost of Revenue TTM 6.11b) / Revenue TTM)
Gross Margin QoQ = 39.46% (prev 40.32%)
Tobins Q-Ratio = 0.94 (Enterprise Value 13.14b / Total Assets 13.95b)
Interest Expense / Debt = 0.88% (Interest Expense 43.0m / Debt 4.86b)
Taxrate = 18.77% (140.0m / 746.0m)
NOPAT = 945.6m (EBIT 1.16b * (1 - 18.77%))
Current Ratio = 1.44 (Total Current Assets 6.06b / Total Current Liabilities 4.21b)
Debt / Equity = 1.04 (Debt 4.86b / totalStockholderEquity, last quarter 4.66b)
Debt / EBITDA = 2.10 (Net Debt 3.24b / EBITDA 1.54b)
Debt / FCF = 5.35 (Net Debt 3.24b / FCF TTM 606.0m)
Total Stockholder Equity = 4.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 635.0m / Total Assets 13.95b)
RoE = 14.61% (Net Income TTM 635.0m / Total Stockholder Equity 4.35b)
RoCE = 14.52% (EBIT 1.16b / Capital Employed (Equity 4.35b + L.T.Debt 3.67b))
RoIC = 21.08% (NOPAT 945.6m / Invested Capital 4.49b)
WACC = 5.33% (E(10.20b)/V(15.06b) * Re(7.53%) + D(4.86b)/V(15.06b) * Rd(0.88%) * (1-Tc(0.19)))
Discount Rate = 7.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.36%
[DCF] Terminal Value 83.93% ; FCFF base≈510.4m ; Y1≈413.3m ; Y5≈287.1m
[DCF] Fair Price = 32.52 (EV 8.81b - Net Debt 3.24b = Equity 5.56b / Shares 171.1m; r=5.90% [WACC]; 5y FCF grow -22.80% → 2.90% )
EPS Correlation: 20.21 | EPS CAGR: -10.81% | SUE: -1.10 | # QB: 0
Revenue Correlation: -50.30 | Revenue CAGR: -1.65% | SUE: -1.39 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.84 | Chg7d=+0.042 | Chg30d=-0.154 | Revisions Net=-3 | Analysts=5
EPS current Year (2026-12-31): EPS=4.14 | Chg7d=-0.023 | Chg30d=-0.200 | Revisions Net=-13 | Growth EPS=+13.9% | Growth Revenue=-2.1%
EPS next Year (2027-12-31): EPS=4.55 | Chg7d=-0.014 | Chg30d=-0.207 | Revisions Net=-9 | Growth EPS=+10.0% | Growth Revenue=+2.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.7% (Discount Rate 7.9% - Earnings Yield 6.2%)
[Growth] Growth Spread = -11.4% (Analyst -9.6% - Implied 1.7%)
P/E Trailing = 16.1189
P/E Forward = 13.4409
P/S = 1.0043
P/B = 2.4845
P/EG = 1.0419
Revenue TTM = 10.16b EUR
EBIT TTM = 1.16b EUR
EBITDA TTM = 1.54b EUR
Long Term Debt = 3.67b EUR (estimated: total debt 4.86b - short term 1.19b)
Short Term Debt = 1.19b EUR (from shortTermDebt, last quarter)
Debt = 4.86b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.24b EUR (from netDebt column, last quarter)
Enterprise Value = 13.14b EUR (10.20b + Debt 4.86b - CCE 1.92b)
Interest Coverage Ratio = 6.26 (Ebit TTM 1.16b / Interest Expense TTM 186.0m)
EV/FCF = 21.69x (Enterprise Value 13.14b / FCF TTM 606.0m)
FCF Yield = 4.61% (FCF TTM 606.0m / Enterprise Value 13.14b)
FCF Margin = 5.97% (FCF TTM 606.0m / Revenue TTM 10.16b)
Net Margin = 6.25% (Net Income TTM 635.0m / Revenue TTM 10.16b)
Gross Margin = 39.86% ((Revenue TTM 10.16b - Cost of Revenue TTM 6.11b) / Revenue TTM)
Gross Margin QoQ = 39.46% (prev 40.32%)
Tobins Q-Ratio = 0.94 (Enterprise Value 13.14b / Total Assets 13.95b)
Interest Expense / Debt = 0.88% (Interest Expense 43.0m / Debt 4.86b)
Taxrate = 18.77% (140.0m / 746.0m)
NOPAT = 945.6m (EBIT 1.16b * (1 - 18.77%))
Current Ratio = 1.44 (Total Current Assets 6.06b / Total Current Liabilities 4.21b)
Debt / Equity = 1.04 (Debt 4.86b / totalStockholderEquity, last quarter 4.66b)
Debt / EBITDA = 2.10 (Net Debt 3.24b / EBITDA 1.54b)
Debt / FCF = 5.35 (Net Debt 3.24b / FCF TTM 606.0m)
Total Stockholder Equity = 4.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 635.0m / Total Assets 13.95b)
RoE = 14.61% (Net Income TTM 635.0m / Total Stockholder Equity 4.35b)
RoCE = 14.52% (EBIT 1.16b / Capital Employed (Equity 4.35b + L.T.Debt 3.67b))
RoIC = 21.08% (NOPAT 945.6m / Invested Capital 4.49b)
WACC = 5.33% (E(10.20b)/V(15.06b) * Re(7.53%) + D(4.86b)/V(15.06b) * Rd(0.88%) * (1-Tc(0.19)))
Discount Rate = 7.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.36%
[DCF] Terminal Value 83.93% ; FCFF base≈510.4m ; Y1≈413.3m ; Y5≈287.1m
[DCF] Fair Price = 32.52 (EV 8.81b - Net Debt 3.24b = Equity 5.56b / Shares 171.1m; r=5.90% [WACC]; 5y FCF grow -22.80% → 2.90% )
EPS Correlation: 20.21 | EPS CAGR: -10.81% | SUE: -1.10 | # QB: 0
Revenue Correlation: -50.30 | Revenue CAGR: -1.65% | SUE: -1.39 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.84 | Chg7d=+0.042 | Chg30d=-0.154 | Revisions Net=-3 | Analysts=5
EPS current Year (2026-12-31): EPS=4.14 | Chg7d=-0.023 | Chg30d=-0.200 | Revisions Net=-13 | Growth EPS=+13.9% | Growth Revenue=-2.1%
EPS next Year (2027-12-31): EPS=4.55 | Chg7d=-0.014 | Chg30d=-0.207 | Revisions Net=-9 | Growth EPS=+10.0% | Growth Revenue=+2.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.7% (Discount Rate 7.9% - Earnings Yield 6.2%)
[Growth] Growth Spread = -11.4% (Analyst -9.6% - Implied 1.7%)